InsidersTradesSigma
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
9
Disclosed sells
0
T+90 hit rate
29%
T+90 mean return
-11.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Huang James, Director. Director active across 5 companies, notably Ziopharm Oncology INC. Aggregated, 15 disclosures have been logged. Split: 9 buys · 0 sell. Total volume traded: €1.5m. History available since 4 March 2021. The latest transaction was filed on 29 May 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations15 total
150,000 shares@ US$2.4774100.0% of flowOrdinary SharesSEC:0001193125-26-253607:0
Ideal exit: 23 Feb 2027 (T+270)
1,112,308 shares@ US$0.141147.4% of flowCommon StockSEC:0000899243-23-005992:0
19,162 shares@ US$3.893210.2% of flowCommon StockSEC:0000899243-22-030690:0
Ideal exit: 3 Jun 2023 (T+270)
24,975 shares@ US$3.74512.6% of flowCommon StockSEC:0000899243-22-030336:0
Ideal exit: 28 May 2023 (T+270)
5,000 shares@ US$3.75022.5% of flowCommon StockSEC:0000899243-22-029897:0
Ideal exit: 21 May 2023 (T+270)
171,116 shares@ US$3.269474.7% of flowCommon StockSEC:0000899243-22-029564:0
Ideal exit: 16 May 2023 (T+270)
80,000 shares0Common StockSEC:0000899243-22-024006:0
80,000 shares0Common StockSEC:0000899243-22-023988:0
5,000 shares0Common StockSEC:0001437749-22-014716:0
50,000 shares@ US$1.9027100.0% of flowCommon StockSEC:0001437749-21-023912
Ideal exit: 16 Jul 2022 (T+270)
50,000 shares@ US$1.902714.27% mcap50.0% of flowCommon StockSEC:0001437749-21-023912:0
Ideal exit: 16 Jul 2022 (T+270)
100,000 shares@ US$1.7150.0% of flowCommon StockSEC:0001209191-21-054824:0
Ideal exit: 29 May 2022 (T+270)
100,000 shares@ US$1.7150.0% of flowCommon StockSEC:0001209191-21-054824
Ideal exit: 29 May 2022 (T+270)
8,333 shares0Common StockSEC:0001209191-21-030740:0
8,333 sharesCommon StockSEC:0001209191-21-030740
15 of 15 declarations
About Huang James
James Huang is a Director at ZIOPHARM Oncology Inc, Windtree Therapeutics Inc, and Alaunos Therapeutics, Inc. In this role, he participates in the governance of the companies and in strategic decision-making. His experience in the biopharmaceutical sector allows him to make significant contributions to board discussions.
